Authors: Lin D, Bitar JSL, Ma I, Yuan Y.
Abstract Summary
Immune checkpoint inhibitors have revolutionized triple-negative breast cancer treatment, but HR+/HER2- tumors remain challenging due to poor immunogenicity. New combination strategies aim to transform “cold” tumors into “hot” ones. Early trials show promise in high-risk HR+ cases, but more data is needed.
Why Brain? ðŸ§
Novel immunotherapy combinations show promise in converting “cold” HR+ breast cancers to “hot” tumors, potentially improving treatment outcomes, though more long-term data needed before routine clinical use.
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
